MARCH5 Antibody #19168
- WB
- IP
Supporting Data
| REACTIVITY | H M R |
| SENSITIVITY | Endogenous |
| MW (kDa) | 25 |
| SOURCE | Rabbit |
Application Key:
- WB-Western Blotting
- IP-Immunoprecipitation
Species Cross-Reactivity Key:
- H-Human
- M-Mouse
- R-Rat
Product Information
Product Usage Information
| Application | Dilution |
|---|---|
| Western Blotting | 1:1000 |
| Immunoprecipitation | 1:200 |
Storage
Protocol
Specificity / Sensitivity
Species Reactivity:
Source / Purification
Background
MARCH5/MARCH-V/MITOL is a ubiquitin E3 ligase localized to the mitochondrial outer membrane that affects mitochondrial dynamics (3-5). MARCH5 has been associated with tumorigenesis, innate immunity, autophagy, apoptosis, and senescence (3-9). Mechanistically, MARCH5 associates with MFN2 and also promotes the ubiquitination of fission proteins DRP1, as well as hFis1 and MFN1 (3-6). Dysregulation of MARCH5 through overexpression, mutation, or knockdown can regulate the turnover of fission and fusion proteins and lead to changes in mitochondrial dynamics (3-6). Studies have shown that elevated levels of MARCH5 in ovarian and breast cancers potentially contribute to tumor growth and metastasis (10,11).
- Xie, L.L. et al. (2018) Cancer Sci 109, 3686-94.
- Kasahara, A. and Scorrano, L. (2014) Trends Cell Biol 24, 761-70.
- Nakamura, N. et al. (2006) EMBO Rep 7, 1019-22.
- Yonashiro, R. et al. (2006) EMBO J 25, 3618-26.
- Karbowski, M. et al. (2007) J Cell Biol 178, 71-84.
- Park, Y.Y. et al. (2010) J Cell Sci 123, 619-26.
- Yoo, Y.S. et al. (2015) Nat Commun 6, 7910.
- Chen, Z. et al. (2017) EMBO Rep 18, 495-509.
- Subramanian, A. et al. (2016) Oncotarget 7, 15986-6002.
- Tang, H. et al. (2019) Cancer Manag Res 11, 201-15.
- Hu, J. et al. (2017) Autophagy 13, 333-44.
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.